|
Orthologous residues
|
|
Dok1 (human): Y398‑p, Dok1 (mouse): Y397‑p, Dok1 (rat): Y397‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), CHO (fibroblast) [EphB1 (human), transfection]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
|
insulin
|
Grb10 (human)
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation, phosphorylation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
RASA1 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
Nck1 (human)
|
SH2, SH3_1
|
Induces
|
|
|
co-immunoprecipitation
|
|